BHQ 880

Drug Profile

BHQ 880

Alternative Names: Anti-DKK1 mAb; Anti-DKKK-1 neutralising antibody (BHQ880); BHQ-880

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MorphoSys; Novartis
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action DKK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV)
  • 20 Aug 2015 BHQ 880 is still in phase-II development for Multiple myeloma in USA and Europe
  • 01 Nov 2013 Novartis completes a phase II trial in Multiple myeloma (treatment naive, monotherapy) in USA, Germany and France (IV) (NCT01302886)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top